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Background: The tumor suppressor p53 is a sequence-specific transcription factor that regulates an extensive network
of coding genes, long non-coding RNAs and microRNAs, that establish intricate gene regulatory circuits influencing
many cellular responses beyond the prototypical control of cell cycle, apoptosis and DNA repair.
Methods: Using bioinformatic approaches, we identified an additional group of candidate microRNAs (miRs) under
direct p53 transcriptional control. To validate p53 family-mediated responsiveness of the newly predicted target miRs
we first evaluated the potential for wild type p53, p63β and p73β to transactivate from p53 response elements (REs)
mapped in the miR promoters, using an established yeast-based assay.
Results: The REs found in miR-10b, -23b, -106a, -151a, -191, -198, -202, -221, -320, -1204, -1206 promoters were responsive to
p53 and 8 of them were also responsive to p63β or p73β. The potential for germline p53 mutations to drive transactivation
at selected miR-associated REs was also examined. Chromatin Immuno-Precipitation (ChIP) assays conducted in doxorubicin-
treated MCF7 cells and HCT116 p53+/+ revealed moderate induction of p53 occupancy at the miR-202, -1204, -1206,
-10b RE-containing sites, while weak occupancy was observed for the miR-23b-associated RE only in MCF7 cells. RT-qPCR
analyses cells showed modest doxorubicin- and/or Nutlin-dependent induction of the levels of mature miR-10b, -23b,
-151a in HCT116 p53+/+ and MCF7 cells. The long noncoding RNA PVT1 comprising miR-1204 and −1206 was weakly
induced only in HCT116 p53+/+ cells, but the mature miRs were not detected. miR-202 expression was not influenced by
p53-activating stimuli in our cell systems.
Conclusions: Our study reveals additional miRs, particularly miR-10b and miR-151a, that could be directly
regulated by the p53-family of transcription factors and contribute to the tuning of p53-induced responses.
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The master regulator p53 is a prominent tumor sup-
pressor gene, functioning in the cell as a tetrameric
(dimer of dimers) sequence-specific transcription fac-
tor, able to bind to two copies of a decameric se-
quence with the RRRCWWGYYY consensus (where
R stands for a purine, W for A/T and Y for a pyr-
imidine) representing the so called p53-response
element (p53-RE) [1]. p53 is known to be inducible
in response to a large number of cellular stress sig-
nals that, besides genotoxic stress, include carbon* Correspondence: ciribilli@science.unitn.it
1Laboratory of Transcriptional Networks, Center for Integrative Biology, CIBIO,
University of Trento, Trento, Italy
Full list of author information is available at the end of the article
© 2013 Bisio et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand oxygen deficiencies, perturbations of the transla-
tion apparatus, excessive proliferation signals, alter-
ation in microtubule dynamics [2,3]. There are >100
established p53 targets genes that link p53 to cell
cycle arrest, apoptosis, DNA repair and inhibition of
angiogenesis [3-6]. More recently, p53 was demon-
strated to modulate the expression of genes able to
modify glucose as well as lipid metabolism, induction
of autophagy, immune responses and cell motility
[7-11].
A direct role of p53 on the activation of microRNA
(miRs) expression as well as a role on selective maturation
of microRNA precursors has been recently established
[12,13]. miRs are small non coding RNAs typically of 21–
25 nucleotides in length that regulate gene expression byd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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senger RNAs including those coding for oncogenes and
tumor suppressor proteins [14]. Dysregulation in miR ex-
pression has been reported in various cancers and can
contribute to tumorigenesis [15]. The first evidence of a
p53-dependent regulation of miR genes was provided by
He et al., who identified a family of miRs, namely miR-
34a-c, whose expression reflected the p53 status [16]. The
authors demonstrated that genes encoding miR-34 family
cluster were direct transcriptional targets of p53 and that
their induced expression levels upon genotoxic or onco-
genic stress was dependent on p53 expression, both
in vitro and in vivo. Moreover, He et al. identified the DNA
sequences responsible for the p53 responsiveness of those
miRs. A year later another group of miRs, (miR-192, -194
and −215) was identified as targets of p53 and their abil-
ity to increase the level of CDKN1A (p21CIP1) and to
function as drivers of cell cycle arrest was established
[17]. Examples of feedback loops or regulatory circuits
comprising p53, a target miR and target mRNAs were dis-
covered. For example, p53-directed repression of c-Myc
has also been linked to p53-dependent induction of miR-
145 [18]. miR-107 was demonstrated to be activated by p53
and to cooperate in its cancer suppressive function through
the inhibition of HIF-1β and, consequently, tumor angio-
genesis [19]. The p53 targeted miR-34a was shown to
modulate SIRT1 [20]. More recently, Jin et al. surprisingly
found that p53 directly induced the transcription of miR-
149*, which in turn can target the glycogen synthase
kinase-3α mRNA, resulting in elevated expression of Mcl-1
and resistance to apoptosis in melanoma cells, thus provid-
ing a rational explanation for the poor ability of p53 to sup-
press melanoma progression [21].
Furthermore, it has been demonstrated that p53 itself
can be indirectly activated by the miR-29 family mem-
bers (miR-29a, -29b and -29c), which inhibit the ex-
pression of p85 alpha (the regulatory subunit of the
phosphatidylinositol-3 kinase, PI3K) and CDC42 (Cell
division cycle 42, a Rho family GTPase), thereby de-
creasing their inhibitory effect on p53 [22]. Alterna-
tively, miRs can also negatively regulate p53 expression
as observed for miR-1285, miR-504, miR-33, miR-380,
miR-30d, miR-25 and miR-125b [23-28].
The mechanisms regulating in vivo p53 transactivation
specificity still need to be fully understood, but require in
most cases the interaction of p53 with its response elem-
ent sequences (REs) at target promoters [4]. Recent evi-
dences, including our studies using functional as well as
DNA binding assays in yeast or mammalian cells or with
cell extracts, demonstrated that maximal transactivation
potential requires adjacent dimer binding sites [29-34]. A
spacer between dimer sites even of 1 or 2 nucleotides con-
ferred a negative impact, particularly for the p53-related
protein p73 [31,35,36]. We also established that p53 canstimulate transcription, albeit at a reduced levels, from
noncanonical response elements (half-sites and ¾ sites)
[31], that do not provide for a p53 tetramer binding site.
The same sequence-specific requirements that were shown
to maximize the transactivation potential from full-site
REs, appeared to be valid for the half-site REs [31]. This
information is relevant to optimize pattern-based motif
searches aiming at identifying functional p53 response ele-
ments within genomes [37-39].
In this study we used a regression-based predictor for
p53 transactivation [39], to identify additional p53-
target miRs through the presence of functional p53-REs
in their promoter regions or in promoter regions of long
noncoding RNA that are precursors of those miRs. We
then used a yeast-based functional assay to determine
the relative transactivation capacity of p53 family proteins
towards the identified REs and Chromatin Immuno-
Precipitation (ChIP) assays in human cells to investigate
genotoxic-stress dependent p53 occupancy at the chromo-
somal sites containing those REs. Changes in the expres-
sion levels for mature miRs or precursors were measured
by real-time qPCR using cell lines and treatments probing
the direct involvement of p53. We propose miR-10b, -23b
and -151a to be included in the list of direct p53 target
miRs contributing to the fine-tuning of p53-induced
responses.
Methods
Yeast reporter strains and media
We constructed a panel of 16 reporter strains in the bud-
ding yeast Saccharomyces cerevisiae containing the Firefly
luciferase gene under the control of putative p53-REs (see
Table 1 for the RE sequence and location with respect to
miR genomic coordinates) predicted to control the expres-
sion of miR -10b, -23b, -34a, -106a, -145, -151a, -191,
-198, -202, -221, -320, -328, -455, -671, -1204, -1206. To
this aim we took advantage of the methodology of the
well-established delitto perfetto approach for in vivo muta-
genesis using oligonucleotides [40] starting with the mas-
ter reporter strain yLFM-ICORE [41]. The strain contains
the luciferase cDNA integrated at the chromosome XV
downstream a minimal promoter derived from the CYC1
gene. The ICORE cassette is located 5′ to the minimal
promoter and enables high efficiency targeting of the locus
by oligonucleotides that contain desired RE sequences.
The targeting events were followed by phenotypic selec-
tion and clones examined by colony PCR and direct DNA
sequencing (BMR Genomics, Padua, Italy).
Yeast cells were grown in 1% yeast extract, 2% peptone,
2% dextrose with the addition of 200 mg/L adenine (YPDA
medium). Selective minimal plates lacking tryptophan or
leucine but containing adenine (200 mg/L) and dextrose as
carbon sources were used (transformation in yeast and
luciferase-based assay).
Table 1 List of predicted p53-REs mapped nearby miR genes









DIMER 1 Spacer DIMER 2
Consensus - - - - RRRCATGYYY N = 0 - 13 RRRCATGYYY
miR-34a Chr 1 - 9242203 - 30,476 bp Intergenic + 123 bp GGGCTTGCCT - GGGCTTGTTC
miR-10b Chr 2 - 177013750 - 1,281 bp HOXD3 + 12,065 bp TAACTCGTTG GCTTTGACCTGTCT GAACAAGTCG
miR-23b Chr 9 - 97818687 - 28,803 bp C9orf3 + 135 bp AGGTCAGTCA TG GGACATGTCC
miR-106a Chr X - 133309906 - 5,678 bp Intergenic - GTTATGTTC ATGTGCTCAT GTGCATGCCC
miR-145 Chr 5 - 148786372 - 23,837 bp Intergenic + 68 bp GCACCCGCCT CGCCCCAATACG GGGCTTGCCT
miR-151a Chr 8 - 141734774 - 2,349 bp PTK2 - 75,874 bp TGGCTTGTTT - TGGCAAGTTC
miR-191 Chr 3 - 49063594 - 5,543 bp DARLD3 + 5,103 bp GACCTTGTCT TGCTTCC AGCCATGTCA
miR-198 Chr 3 - 120112741 + 1,774 bp FSTL1 - 57,359 bp AGGCAAGCTT - CAACAAGCCG
miR-202 Chr 10 - 135058647 + 2,368 bp RP13-49115.5 - 2,748 bp GGGCATGTCT - TGGCAAGCCT
miR-221 Chr X - 45599946 + 5,639 bp Intergenic - GAACATGCAT - GCACATGTTT
miR-455 Chr 9 - 116880600 - 91,114 bp COL27A1 - 49,395 bp CTTCCTGCAT AAGGCTTGGCGG GCGCAAGCCC
miR-320a Chr 8 - 22095461 + 7,014 bp Intergenic - AGGCATGGTG - CGGCATGCCT
miR-328 Chr 16 - 67331546 - 95,322 bp ELMO3 + 98,475 bp CGGCAAGTCC C CAGCCAGTTC
miR-671 Chr 7 - 150896632 - 38,875 bp CHPF2 - 32,953 bp GGTCCAGCCC TCTGGCCCCC CAACAAGTCT
miR-1204 Chr 8 - 128808017 - 191 bp PVT1 + 1,238 bp CGACAAGTTG - AGACTTGTTC
miR-1206 Chr 8 - 129002467 - 18,677 bp PVT1 + 1,037 bp GGGCTAGTGA - AGGCATGTCT
miR name, genomic location of the predicted p53-RE (including chromosome number and genomic coordinates according to BLAT tool in UCSC Genome Browser,
http://genome.ucsc.edu/), presence and distance from an overlapping primary transcript, p53 RE sequence and position relative to the miR sequence (obtained
through the miRBase tool, http://www.mirbase.org/) are presented. p53-RE organization is shown grouping nucleotides in Dimer 1, Spacer (if any) and Dimer 2,
according to the p53 consensus (in bold).
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For the expression of p53 family protein in yeast we used
available CEN/ARS expression vectors (pTSG- or pLSG-
based) harbouring alternatively the cDNA wild-type of
p53, p63 or p73 under the control of the GAL1,10 indu-
cible promoter [31]. Among the various isoforms of p53
family members, we selected the full-length wild type p53
and the TA-p63β and TA-p73β isoforms as they showed
the maximal transactivation potential in our experimental
settings. The expression levels were modulated by the
concentration of galactose in the culture medium (0.008%,
0.128% or 1%). The whole panel of 104 p53 germline mis-
sense mutants from the IARC R11 database (http://p53.
iarc.fr) cloned in the pLS-Ad vector (providing for a con-
stitutive expression of p53 mutants) [42] were used to test
transactivation capability towards the miR-34a p53 RE.
The pRS-314 or pRS-315 empty vectors were included as
controls; these vectors contain respectively the TRP1 (as
pTSG-) or LEU2 (as pLSG-) yeast selectable markers.
Luciferase assays in yeast
The p53 family responsiveness of miRNA-associated REs
was examined by transforming the panel of yLFM-RE
strains with the p53 expression vectors. Transformants
were obtained using the LiAc method and selected on
minimal plates lacking tryptophan or leucine but contain-
ing adenine (200 mg/L) and dextrose as carbon source toallow respectively the growth of white colonies of normal
shape and to keep the expression of p53 family members
inhibited. After 3 days of growth at 30°C, transformants
were streaked onto the same plates and allowed to grow
for an additional day. For each reporter strain, the basal
luciferase activity was measured from pRS314- or pRS315-
transformants and used to calculate the fold of induction
due to the expression of each p53 family member. For
the luciferase assay we exploited the recently developed
miniaturized yeast assay [43]. Transformant colonies were
grown in 100 μl of the selective medium with 2% raffinose
as carbon source (raffinose result in basal level of expres-
sion from the GAL1,10 promoter), supplemented with dif-
ferent concentrations of galactose (0.008% and 0.128% for
p53; 0.008% and 1% for the other members of the family,
to obtain a low, moderate or high expression of the pro-
teins) in a transparent 96-well plate and incubated under
150 rpm shaking for 16–24 hours at 30°C. OD600 was
measured directly in the multi-well plate to normalize for
cell density using a multilabel plate reader (Infinite M200-
Pro, Tecan, Milan, Italy). 10 μl of cells suspensions were
transferred to a white 384-well plate (Brand, Milan Italy)
and mixed with an equal volume of PLB buffer 2X (Passive
Lysis Buffer, Promega, Milan, Italy). After 15 minutes of
shaking at room temperature, 10 μl of Firefly luciferase
substrate (Bright Glo Luciferase Reporter Assay, Pro-
mega) were added. Luciferase activity was measured at
Bisio et al. BMC Cancer 2013, 13:552 Page 4 of 13
http://www.biomedcentral.com/1471-2407/13/552the plate reader, using a luminescence program with 1”
integration time.
Cell lines and treatments
The human breast adenocarcinoma-derived MCF7 cell
line was obtained from the InterLab Cell Line Collection
bank, ICLC (Genoa, Italy). The colon adenocarcinoma
HCT116 (p53+/+) cell line and its p53−/− derivative were
obtained from B. Vogelstein’s group (The Johns Hopkins
Kimmel Cancer Center, Baltimore, Maryland, USA).
Cells were normally maintained in DMEM or RPMI sup-
plemented with 10% FCS and antibiotics (100 units/ml
penicillin plus 100 mg/ml streptomycin).
Cells were treated for 24 hours with 1.5 μM doxorubicin
(DXR) or 10 μM Nutlin-3A for p53 stabilization/activation.
Stock solutions of Nutlin-3A were dissolved in 100%
DMSO (stock solution 10 mM); DXR was dissolved in
H2O (stock 10 mM). DXR was bought from Sigma-
Aldrich® (Milan, Italy) whereas Nutlin-3A from Alexis® Bio-
chemicals (Enzo Life Sciences, Exeter, UK). All the treat-
ments were performed when cells reached 70-80% of
confluence.
RNA extraction and RT-qPCR
RNA extraction from human cell lines was done with
Trizol reagent (InVitrogen, Life Technologies, Milan, Italy)
following the manufacturer’s protocol. Cells were treated
with 1.5 μM DXR or 10 μM Nutlin-3A for 24 hours prior
to Trizol extraction. Quantification of mature microRNA
expression was carried out using TaqMan MicroRNA
Assay kits according to the manufacturer’s protocol (Ap-
plied Biosystems, Life Technologies), as described in
Barbareschi et al. [44]. Specifically, ready-made TaqMan
MicroRNA Assays (containing microRNA-specific for-
ward and reverse PCR primers and microRNA-specific
Taqman MGB probe) were used for the investigation of
miR-34a (ABI P/N 000426), miR-10b (ABI P/N 000388),
miR-23b (ABI P/N 000400), miR-151a (ABI P/N 002254),
and miR-202 (ABI P/N 002363). We also quantified the
U6 small nuclear RNA (RNU6B) (ABI P/N 4373381) as an
endogenous control to normalize the levels of target
microRNA. Complementary DNA was generated using
the Taqman MicroRNA Reverse Transcription (RT) Kit
(ABI P/N 4366596) according to the manufacturer’s in-
structions. Reverse transcriptase reactions contained 10 ng
of total RNA as the template, 3 μl of gene specific stem-
loop RT primer, 1.5 μl of 10X RT buffer, 0.15 μl of
100 mM dNTPs, 1 μl of MultiScribe reverse transcriptase,
and nuclease-free water. The 15 μl reactions were incu-
bated on a GeneAmp PCR System (Bio-Rad, Hercules,
CA) for 30 minutes at 16°C, 30 minutes at 42°C, 5 minutes
at 85°C, and then kept at 4°C. Quantitative RT-PCR was
carried out using the Rotorgene 6000 (Corbett Life Sci-
ence, Ancona, Italy) in 20 μl PCR reactions containing1.33 μl of RT product, 10 μl of FastStart TaqManProbe
Master (Roche, Milan, Italy, P/N04673417001), 7.67 μl of
nuclease–free water, and 1 μl of MicroRNA Assay (Ap-
plied Biosystems, Life Technologies) buffer. Reactions
were incubated at 95°C for 10 minutes, followed by 40 cy-
cles of incubation at 95°C for 15 seconds and at 60°C for
1 minute. The quantification of protein coding mRNAs
was performed using a Sybr green RT-qPCR approach.
Total RNAs extracted with Trizol were converted using the
RevertAid™ First Strand cDNA Synthesis Kit containing the
M-MuLV Reverse Transcriptase following the manufac-
ture’s recommendation (Thermo Scientific Inc., M-Medical,
Milan, Italy). qPCR were carried out using the KAPA Sybr
Green PCR mix (Kapa Biosystems, Resnova, Rome, Italy)
with 12.5 ng of cDNA on the CFX384 real-time PCR detec-
tion system (BioRad, Milan, Italy). Primers were picked
using the Primer-BLAST online tool (http://www.ncbi.nlm.
nih.gov/tools/primer-blast/); sequences are available upon
request. The Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and β2-microgobulin (B2M) were used as refer-
ence genes for normalization.
In all the qPCR assays, the threshold cycle data (Ct) and
baselines were determined using auto settings. The Ct
value was defined as the fractional cycle number at which
the fluorescence passed a fixed threshold. Fold changes
were calculated using the comparative Ct method (ΔΔCt).
Western blot analysis
To evaluate p53, p63 or p73 protein levels in yeast we cul-
tured transformant colonies for 24 hours using selective
medium containing 0.128% (p53) or 1% (p63β and p73β)
galactose to induce the expression. Yeast cells were har-
vested, washed in ddH2O and lysed mechanically with
glass beads as previously described [45]. 15 μg (p53) and
75 μg (p63β and p73β) were loaded on a 7.5% Acrylamide
gel and separated by SDS-PAGE. DO-1, 4A4 (Santa Cruz
Biotechnology, Milan, Italy) and ER-15 (Calbiochem,
Merck, Millipore, Milan, Italy) antibodies were used for
p53, p63 and p73 immunodetection, respectively. Phos-
phoGlycerate Kinase 1 (PGK1, detected by Ab clone num-
ber 22C5D8, InVitrogen, Life Technologies) was used as
loading control.
To demonstrate p53 stabilization and activation upon
treatment with doxorubicin or Nutlin-3A, MCF7, HCT
p53+/+ and HCT p53−/− cells were harvested 16–18 hours
after the treatments and lysed using RIPA (Radio Immuno
Precipitation Assay) buffer (150 mM sodium chloride; 1.0%
NP-40; 0.5% sodium deoxycholate; 0.1% SDS, sodium dode-
cyl sulphate; 50 mM Tris, pH 8.0) supplemented with Pro-
tease Inhibitors cocktail (Roche, Milan, Italy) [46]. 50 μg of
the soluble extracts were loaded on a 12% Acrylamide gel
and separated by SDS-PAGE. p53 and p21 endogenous
protein levels were detected with incubation with monoclo-
nal antibodies (DO-1 and C-19 clones against p53 and p21
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phosphate dehydrogenase protein (GAPDH, Ab clone 6C5,
Santa Cruz Biotechnology) served as loading control. All
antibodies were diluted in 1% non-fat skim milk dissolved
in PBS-0.1% Tween20.
Chromatin immunoprecipitation (ChIP) analysis
HCT116 p53+/+ and HCT116 p53−/− or MCF7 cells were
grown on 150-mm dishes and treated with 1.5 μM doxo-
rubicin for 24 hours. Proteins were cross-linked with
DNA by addition of 1% formaldehyde. After 10 minutes
incubation at room temperature the reaction was stopped
by addition of glycine at a final concentration of 0.125 M
followed by additional incubation for 5 minutes. Cells
were washed twice with 10 ml cold PBS, harvested in 1 ml
PBS plus protease inhibitors (PI) (Complete EDTA-free,
Roche), and lysed using an SDS lysis buffer (1% SDS,
50 mM Tris–HCl pH 8, 20 mM EDTA, 0.1 mg/mL Soni-
cated Salmon sperm DNA, 1X PI). In order to eliminate
soluble p53 protein, lysates were incubated with gently
shaking for 10 min and insoluble material was collected
by centrifugation at 800 g at 4°C for 5 min. Pellets were re-
suspended in 0.5 ml of sonication buffer containing 0.25%
SDS, 200 mM NaCl, 100 mg/ml of sonicated salmon
sperm DNA and protease inhibitors and were sonicated to
shear DNA to lengths between 150 and 500 base pairs
(bp) using a Misonix S-4000 sonicator with a plate horn
(Misonix, Newtown, Connecticut, USA). After 10-fold di-
lution in ChIP dilution buffer (16.7 mM Tris, 0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl), IPs
were carried out overnight at 4°C with 2 μg of anti-p53
(DO-1, Santa Cruz Biotechnology) or 2 μg of normal IgG
as a negative control. Fifty microliters of Dynabeads pro-
tein G magnetic beads (Invitrogen, Life Technologies)
were added to each sample for 2–3 h, and the beads were
then washed as indicated in the Upstate Biotechnology
ChIP protocol. DNA was eluted firstly with 100 μL of TE
with 1% SDS for 10 min at 65°C and a second time with
150 μL of TE with 0.67% SDS for an additional 10 min at
65°C. The cross-links were reversed overnight at 65°C.
RNase A was added and incubated at 37°C for 30 min and
then Proteinase K for 2 h at 56°C. DNA was then purified
by QIAquick PCR purification KIT columns (Qiagen,
Milan, Italy). Immunoprecipitated DNA was analyzed
for p53 occupancy on selected chromosomal sites sur-
rounding the predicted miR-associated p53 REs by
RealTime-qPCR and fold enrichment of p53 binding to
the respective DNA sequences was calculated by the
comparative Ct method as described previously [47].
RealTime-qPCR was carried out with the KAPA SYBR
Green PCR mix (Kapa Biosystems, Resnova) and all
primers were checked for equal amplification efficiency.
All PCR results were normalized to input controls. Three
different DNA loci were used as ChIP negative controls(the CCNB1 exon 9, the Actin and GAPDH promoter).
Sequences of all ChIP primers are available upon request.Results and discussion
Identification of functional p53 response elements in
miR genes
We applied a predictor tool for p53 RE-transactivation po-
tential [39] to identify candidate p53 REs within regulatory
regions of miR genes or promoter regions of long noncod-
ing RNAs containing pri-miR clusters. Based on this ana-
lysis several novel p53 target miRs can be predicted
(Table 1). To confirm p53 responsiveness of the identified
p53 REs we first applied a well-established quantitative re-
porter assay in the budding yeast Saccharomyces cerevisiae
[37,43]. This assay was chosen as it provides a defined ex-
perimental system to measure transactivation potential of
a panel of REs each cloned at the same chromosomal loca-
tion in isogenic derivative reporter strains where wild type
or mutant p53, as well as p53-related proteins p63 and
p73, can be expressed, one at a time, from a inducible pro-
moter [43]. 15 candidate miR-associated p53 REs were
studied. The validated miR-34a p53 RE was included as a
positive control. The results indicated that most of the
identified p53-REs could be transactivated at low to mod-
erate levels by wild type p53 (Figure 1A). As expected
the responsiveness was proportional to p53 expression
levels (Figure 1A and B). Based on results obtained
both with low and high p53 expression, REs from miR-
34a, -10b, -202, -1204 were highly responsive (HR), from
miR-23b, -151a, -221, -320, -1206 were moderately-respon
sive (MR), from -106a, -191, -198 were weakly responsive.
Putative REs from miR-145, -328, -455, -671 were not re-
sponsive to p53 in the yeast-based assay.
Next we tested p63 and p73 responsiveness of the same
panel of REs, using the transactivation competent, TA-
p63β and TA-p73β isoforms for these proof-of-principle
experiments, as they exhibit higher relative transactivation
potential compared to N-terminal truncated ΔN- and also
compared to TA-p63α and TA-p73α isoforms [37]. As ex-
pected the transactivation potential of p63 β and p73β
were much lower compared to p53 (Figure 1C and D).
Only a subset of p53-responsive REs was active with p63
and p73 and included miR-34a, -202 and −1204 REs. Fur-
thermore, differences in relative transactivation potential
were observed in the comparison of the three family mem-
bers. For example, miR-34a and −1204 were more respon-
sive to p63 than to p73. Furthermore, we observed
examples of selective lack of responsiveness: p73 towards
miR-10b and −221 REs; p63 towards mir-151a. To verify
the protein expression of the three p53 family members in
yeast after galactose induction (0.128% and 1% galactose for
p53 or p63 and p73, respectively, to match the experimen-
tal conditions used for the luciferase assays) we performed
Figure 1 p53 family members can transactivate p53-REs found in miR-associated promoter regions. A-B) Transactivation potential of p53
protein tested on a panel of 15 putative p53-dependent miR-REs and miR-34a-RE (a positive control) using the yeast functional assay. The
expression of p53 was modulated by increasing concentrations of galactose in the culture medium (A, 0.008%: a moderate p53 expression;
B, 0.128%: high p53 expression). C-D) The same panel of p53 miR-REs was tested using the other members of the p53 family p63 and p73 (gray
and black bars respectively). The expression of p63β and p73β isoforms was induced using two different concentrations of galactose (C, 0.008%:
moderate expression; D, 1%: maximal induction). Results are presented as fold of induction calculated over an empty expression vector. Bars plot
the averages and standard deviations of at least three independent biological repeats. (E) Western Blot establishing galactose-dependent
expression of p53, p63 or p73 in yeast. PGK1 was used as reference.
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tion factor (Figure 1E).
For 5 REs, representative of strong, moderate, weak, and
nearly-absent responsiveness to wild type p53, the func-
tional assay was extended to five p53 missense germline
mutations, of which three retain partial function (A138S,
C141Y, R337C) and two are loss of function (A138P,
R175H) [42]. Similar results were obtained with the respon-
sive REs, confirming the functional classification of the p53
mutants examined (Figure 2); for example, A138S was
near-wild type, while R337C was weakly active (<10% of wt
activity) and 141Y almost inactive (<5% of wt activity).
Given the important role of miR-34a as a positive modula-
tor of p53-mediated responses [48,49] and our recent stud-
ies indicating that p53 mutant transactivation capacity can
correlate with clinical variables in Li-Fraumeni patients
[42,50], we decided to use the miR-34a reporter strain to
examine the entire panel of 104 germline p53 alleles de-
scribed in the R11 release of the p53-mutant IARC data-
base [42]. The vast majority, 83 out of the total 104 alleles
(79.8%) were considered loss of function (LOF, defined for
the cases where a residual transactivation was lower than
25% of the wild type p53 activity). Eight (7.7%) retained a
partial function phenotype (activity between 75% to 25% of
wt p53), while 9 (8.7%) had the same transactivation poten-
tial as the wild-type. Interestingly, 4 alleles (R337H, H365Y,
S366A, P82L) showed a transcriptional activity higher thanFigure 2 p53-REs found in miR promoters can be used to classify p53
missense mutants representative of partial function (A138S, C141Y, R337C)
transactivation from 5 p53 miR-REs using the yeast functional assay. Yeast t
luciferase activity was measured using the miniaturized assay format [43]. B
independent biological repeats.wild-type p53 (>125%) and can be considered as super-
transactivating alleles (ST). All the results are summarized
in the Additional file 1: Table S1. As expected, while the
vast majority of the LOF-p53 alleles hit the central portion
of the p53 protein, associated with DNA binding capacity,
the WT-, PT-, and ST-alleles were preferentially confined
to the extremities (both N- or C-terminal domains). Com-
pared to our previous classification based on four p53 REs
derived from P21, MDM2, BAX and PUMA, 8 additional
alleles are classified as LOF with miR-34a, while one
(I305M) would change from LOF to partial function.
Overall these results identify a panel of p53 REs that
based on the comparison with well-established REs from
coding genes [31,37] suggest the potential for p53-
mediated control of miR gene expression in vivo. Further,
results suggested that miRs could be selectively or more
specifically (e.g. -10b, -151a; -198) targeted by individual
p53 family proteins, possibly contributing to the distinct-
iveness of the regulated networks and biological outcomes.
Finally, the identified p53 miR-REs can be used to refine
the functional classification of cancer associated p53 mu-
tant alleles.
p53-occupancy at endogenous miR-associated promoters
in human cells
As the yeast functional data provided us information pre-
dominantly on the nature of the mapped p53-REs,germline alleles associated with Li-Fraumeni Syndrome. Five p53
or loss-of-function (A138P, R175H) germline p53 alleles were tested for
ransformants were cultured over-night in selective medium and the
ars represent the averages and standard deviations of at least three
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ectopic context, we analyzed the correspondence of our
results with the ability of p53 to physically interact with
those sequences in their natural context in mammalian
cells treated with a genotoxic agent (doxorubicin, DXR)
known to result in p53 stabilization and activation [51,52].
To this aim we treated HCT116 p53+/+, HCT116 p53−/−
and MCF7 (p53 wt) cells with 1.5 μM DXR for 24 hours
and performed ChIP assays. We selected all the miR pro-
moters with REs classified as HR and some of the MR ac-
cording to the p53 responsiveness in the yeast assay. In
HCT116 p53+/+ cells, DXR-induced p53 occupancy was
observed for all chromosomal coordinates surrounding
miR-associated REs with the only exception of miR-23b.
The relative increase in occupancy was comparable for
miR-202 and miR-1204 sites to the well-established p53
target P21-5′ RE region and the p53-miR-34a target
(Figure 3A and B). As expected in HCT116 p53−/− cells
we did not find any occupancy, confirming the specificity
of the assay. The experiment was repeated in another p53
wild-type cell line, MCF7, using IgG as a control of IP spe-
cificity. Doxorubicin-induced occupancy was observed for
all sites examined, including miR-23b. In particular, miR-
202 and miR-10b promoters showed the highest relative
induction of p53 occupancy (Figure 3C and D).
Downstream of and consistent with the yeast-based re-
sults, ChIP assays further supported the putative function
of the identified p53 REs in modulating p53-mediated re-
sponsiveness of miR genes. However, the correlation be-
tween occupancy and transactivation is not direct, nor
linear [4]. p63 and p73 occupancy was not investigated
and awaits further studies to clarify the contribution of
p53 family proteins on miR gene expression.
Doxorubicin responsiveness of identified p53 target miRs
in p53 wild type human cells
With the yeast-based assays we established the potential
for p53-mediated transactivation of p53 REs associated
with miR sites, while ChIP experiments established ac-
cessibility and potential recruitment of p53 at those sites.
Next we examined if the expression levels of mature or
precursor miR transcripts could be modulated by treat-
ments resulting in p53 activation using again the
HCT116 p53+/+, HCT116 p53−/− and MCF7 cell line
systems. The results indicated that of miR-10b, -151a
and -23b are p53-responsive (Figure 4A). Consistent
with ChIP analysis higher induction levels of mature
miR-10b and -23b in response to DXR were observed in
MCF7 than in HCT116 p53+/+ cells. The treatment did
not result in miR induction in HCT116 p53−/− cells, in
fact some repression was apparent, particularly for miR-
23b (Figure 4A). In contrast to RE transactivation poten-
tial and p53 occupancy studies, miR-202 expression did
not change after the genotoxic treatment (Figure 4).Unfortunately, we were not able to measure miR-1204
or miR-1206 as the expression in these cells appeared to
be below the detection limit of the qPCR in these cell
lines (data not shown).
To exclude any impact of the miR maturation processes
or low sensitivity of the mature miR assay systems, we also
selected primers that can amplify the pre-miR RNA and
performed RT-qPCR for miR-1204, miR-1206, miR-202
and miR-34a (Figure 4B). We also analyzed the expression
of PVT1, the long non-coding RNA transcript comprising
the miR-1204 cluster [53]. Weak, DXR-dependent induc-
tion was observed for PVT1, pre-miR-1204 and pre-miR-
1206 in HCT116 p53+/+ and MCF7 cells. No changes
were observed in HCT116 p53−/− or repression of PVT1
(Figure 4B). To further confirm the direct involvement
of p53 in the transcriptional regulation of those miRs
we also treated the cells with the MDM2 specific inhibitor
Nutlin-3A (Figure 4C). Except for pre-miR-34a, pre-miR-
1204, -1206 and even −202 were responsive to Nutlin treat-
ment only in the HCT116 p53+/+ cell line, highlighting cell
type and treatment dependencies in the expression regula-
tion. The effect of the treatments on p53 stabilization and
activation was examined using western blot (Figure 4D).
miR expression analysis in doxorubicin treated cells
differing for p53 status supported p53-mediated re-
sponsiveness for miR-10b, -151a and, limited to MCF7
cells, also -23b. The levels of induction were in general
comparable to those of miR-34a. Despite the high transac-
tivation potential of the associated p53 REs and the p53
occupancy analysis, the mature miR-202 was not respon-
sive to p53-inducing treatment. This discrepant finding
could be related to the relatively large distance between
the mapped p53 REs and the pri-miR-202 transcript start
site and/or to the inaccessibility of the site due chromatin
structure. The p53 RE sequence does not fall within
DNAse sensitive sites based on ENCODE data. We were
not able to confirm the p53-dependent induction of ma-
ture miR-1204 and −1206 in our cell lines, although we
detected weak induction of the long noncoding RNA con-
taining the miR-1204 cluster and possibly evidence for an
internal transcript comprising pre-miR-1206. A recent
study established p53-dependent induction of Plasmacy-
toma Variant Translocation 1 gene PVT1 and miR-1204
[53] in HCT116 p53 wild type cells treated with doxorubi-
cin. Our results confirm those findings and also suggest
p53 recruitment internally to the PVT1 gene locus to pos-
sibly further modulate miR-1206 independently or in
addition to the activation of the entire miR-1204-1208
cluster. Further studies are needed, including the use of
cell lines expressing higher basal levels of PVT1 to exam-
ine whether miR-1206, and possibly −1207 and −1208
downstream, can be modulated by p53 family proteins
also independently from PVT1 gene transcription. A link
between p53 and modulation of miR-23b was also recently
Figure 3 (See legend on next page.)
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Figure 3 p53 can bind chromatin region surrounding the identified p53 REs in miR genes. A) ChIP assays were performed in HCT116 p53+/+
(gray bars) and HCT116 p53−/− (black bars) upon doxorubicin treatment for 24 hours. The results of Real-Time qPCR are presented as fold of mock
treatment, normalized with respect to the signal obtained with Input DNA. The results from three control locations corresponding to promoter regions
of Actin, GAPDH and exon 9 of CCNB1 genes were averaged and are also presented in panel A (Neg. Ctrls). P21 and miR-34a occupancy were measured
as positive controls. Bars represent average and standard deviations of three independent experiments. C) ChIP assays of MCF7 cells treated with
doxorubicin for 24 hours. Results obtained after ChIP with an antibody against IgG were included as a negative control for the p53 miR-REs. Examples of
agarose gel analysis of standard ChIP-PCR are given in panels B and D. Specifically, panel B shows experiments performed in HCT116 p53+/+ and
p53−/− cells, while panel D presents results from MCF7 cells. The DO-1 p53 antibody was used for immunoprecipitation; NTC, no template control.
Regions surrounding the established P21 and miR-34a p53 REs were examined as positive controls.
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(HPV)-mediated responses through inhibition of p53
function [54]. Our results further confirm miR-23b as a
p53 target miR in other cancer–derived cell lines. A previ-
ous link between p53 and miR-151a, as well as FAK pre-
mRNA that contains miR-151a, was proposed based on
transient silencing of p53 in the hepatocellular carcinoma-
derived HepG2 cells resulting in FAK and miR-151a up-
regulation (Figure S4 in [55]). Our results in different cell
models indicate instead the potential for positive modula-
tion of this miR by doxorubicin treatment in p53 wild type
cells. Bioinformatics-based predictions, transactivation
potential of RE, occupancy and mature miR expression
changes in doxorubicin treated cells, consistently indi-
cate, to our knowledge for the first time, miR-10b as a
p53 target gene.
An expanded role of p53 in the modulation of
microRNA expression
The study of the p53 gene transcriptional networks
continues to raise particular interest in the field due to
the increasing complexity of regulatory circuits and the
functions of the extensive list of target genes spanning
a myriad of different biological pathways. The discov-
ery of p53-target miRs has led to the identification of
several feedback and feed-forward loops that can lead
to fine-tuning of p53-mediated responses. A few p53
target miRs, more prominently miR-34a, have been
shown to act as bona-fide tumor suppressor genes
[56,57]. Multiple evidence, comprising gene expression,
ChIP-seq and phenotypic studies upon gene silencing
or targeting in cell and animal models indicate a com-
plex crosstalk between p53 and the related p63 and
p73 proteins at the level of common and exclusive
coding gene targets [58-61]. An integrated view of
common and p53-family protein specific regulation of
miR genes is however largely missing.
This work led to the identification of new p53 target
miRs (miR-10b; -151a) and also confirmed or extended
recent evidence from the literature (miR-1204, -1206;
-23b). Proof-of-principle experiments also suggested
miR genes worth of further analysis to ascertain aspecific or selective role for p63 or p73 transcription
in their expression. The weak p53-responsiveness to-
wards p53 REs associated with miR-106a, -191, -198,
-221 and −320 was not pursued in this study and awaits
further investigation.
Perhaps surprising is the fact that the miR genes we
propose (miR-10b; -151a) or confirm more in detail
(miR-23b; -1204; -1206) as direct p53 targets do not fit
intuitively with the expected p53-mediated functions. In
fact all these miRs have been proposed to exhibit onco-
genic activities or at least their over-expression has been
correlated to aggressive cancer phenotypes in some tis-
sues [55,62-66]. For example, the established potential
for miR-10b to target both CDKN1A and CDKN2A
mRNAs could in principle result in a p53-directed at-
tenuation circuit of cell cycle arrest and senescence [62].
However, KLF4 mRNA has been described as a miR-10b
target and KLF4 down-regulation in breast cancer cells
has been reported to restore p53 functions leading to
apoptosis [67]. Hence, in specific cellular contexts, it is
possible that the p53-dependent regulation of miR-10b
we discovered could result in a positive feedback loop
stimulating p53 activity. Further, CpG islands upstream
from the miR10b/10b* locus were found to be hyper-
methylated in breast cancers and through ectopic ex-
pression an important role for miR-10b* in cell cycle in-
hibition was established [68].
It is known that miR functions can be highly context
and tissue-dependent and their p53-mediated control in
normal cells could potentially affect biological responses
also not directly related to cell cycle control or apop-
tosis. For example, low levels of miR-23b resulting in
higher levels of its target urokinase-type plasminogen ac-
tivator could promote cervical cancer cell migration
[54]. Finally, increasing evidence link p53 functions to
innate and adaptive immunity and it could be speculated
that miR-23b as well as PVT1 and the miR-1204 cluster
regulation could be relevant in this context [53,69]. Inte-
restingly, functional enrichment analyses of predicted tar-
gets of both miR-10b and -151a showed enrichment for
neuron generation/development and brain-related pheno-
types (uncorrected p-value < 0.05; data not shown).
Figure 4 p53-induced expression of mature and pre-miR genes.
RT-qPCR were performed in HCT116 p53+/+(black bars), HCT116
p53−/− (white bars) and MCF7 (gray bars) cells upon doxorubicin
(A, B) or Nutlin (C) for 24 hours. The expression of the processed
mature miR (A) or of the pre-miR RNA (B, C) was tested. p21 mRNA
expression was measured as p53-dependent positive control. PVT1
non-coding RNA expression levels were measured as additional
evidence of p53-dependent expression of miR-1204 and miR-1206.
Results are presented as fold of induction with respect to the mock
condition. Bars plot average and standard deviations of three
independent experiments. (D) Western Blot establishing stabilization
of p53 protein in doxorubicin and Nutlin treated cells and the
induction of the p53 target gene p21. GAPDH was used [6]
as reference.
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In our study, bioinformatics-based predictions, transacti-
vation potential of putative p53 REs, p53 occupancy at the
endogenous RE positions, and mature miR expression
changes in cell lines differing for p53 status, were com-
bined to identify miRs that are direct transcriptional
targets of wild type p53. We established that miR-10b and
miR-151a are new p53 target genes and also confirmed
cis-mediated regulation by p53 of miR-1204, -1206
and -23b. Further studies are warranted to establish the
biological implications of the newly identified p53 target
miRs.Additional file
Additional file 1: Table S1. Transactivation potential of 104
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